Analysed ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) News Sources
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
10-04-2026
yahoo.com
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
29-03-2026
yahoo.com
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout
20-03-2026
yahoo.com
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ...
13-03-2026
yahoo.com
What is the current price of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The current price of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is $2.72.
ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) since the previous trading day is $-0.19.
ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) since the previous trading day is -6.5292%.
What is the most recent average sentiment score for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The most recent average sentiment score for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The most recent sentiment for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is .
SEC-8K** Filing Available For ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.